Cancer Research UK logo.
SearchDonate
  • Search

A trial comparing pembrolizumab with docetaxel for non small cell lung cancer (KEYNOTE-010)

Overview

Cancer types:

Lung cancer, Non small cell lung cancer (NSCLC)

Status:

Results

Phase:

Phase 2/3

Details

This trial compared pembrolizumab with docetaxel for advanced non small cell lung cancer (NSCLC). The trial was for people:

  • who had already had treatment for their lung cancer with a

  • whose cancer cells produced a protein called PD-L1

  • whose cancer had grown into surrounding tissues or spread elsewhere in the body (advanced cancer)

Recruitment start: 28 February 2013

Recruitment end: 27 February 2015

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Dean Fennell

Supported by

Experimental Cancer Medicine Centre (ECMC)

Merck Sharp & Dohme Ltd

NIHR Clinical Research Network: Cancer

Last reviewed: 16 Oct 2018

CRUK internal database number: 10623

Help and support